Free Trial

BioStem Technologies, Inc. (OTCMKTS:BSEM) Sees Significant Growth in Short Interest

BioStem Technologies logo with Medical background

Key Points

  • Short interest in BioStem Technologies, Inc. increased dramatically by 174.3% in July, reaching a total of 214,800 shares by July 31.
  • The company has a market capitalization of $117.92 million and its shares opened at $7.04 on Friday, with a 12-month trading range between $5.02 and $28.26.
  • BioStem Technologies focuses on developing pharmaceutical and regenerative medicine products aimed at treating various medical conditions, including joint pain and autoimmune diseases.
  • Need better tools to track BioStem Technologies? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

BioStem Technologies, Inc. (OTCMKTS:BSEM - Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 214,800 shares, agrowthof174.3% from the July 15th total of 78,300 shares. Approximately1.3% of the shares of the company are short sold. Based on an average daily trading volume, of 76,900 shares, the days-to-cover ratio is currently 2.8 days. Based on an average daily trading volume, of 76,900 shares, the days-to-cover ratio is currently 2.8 days. Approximately1.3% of the shares of the company are short sold.

BioStem Technologies Stock Down 7.6%

BioStem Technologies stock traded down $0.49 on Wednesday, hitting $5.99. The company's stock had a trading volume of 98,699 shares, compared to its average volume of 64,054. The firm has a market cap of $100.33 million, a P/E ratio of 5.25 and a beta of -0.29. The company has a fifty day moving average price of $11.65 and a 200-day moving average price of $12.14. BioStem Technologies has a one year low of $5.02 and a one year high of $28.2565.

About BioStem Technologies

(Get Free Report)

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.

Further Reading

Should You Invest $1,000 in BioStem Technologies Right Now?

Before you consider BioStem Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioStem Technologies wasn't on the list.

While BioStem Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Follow the Money: 5 Stocks Institutions Are Buying NOW
Strong Earnings? Market Says NVIDIA-Level Growth or Be Forgotten
Palantir’s Soaring Valuation—Justified or Overhyped?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines